Skip to main content
 
 
 
MENU
VISIT JANSSEN GLOBAL

EMEA
change location▼

Search
Search
COVID-19 UPDATES >

VISIT JANSSEN GLOBAL

COVID-19 UPDATES >
Janssen EMEA › Media Center

Media Center

The Media Center is intented to provide resources for media professionals only. It is not inteded for use by healthcare professionals, patients or the general public. To access, please confirm that you are an accredited member of the press. I hereby confirm that I am an accredited member of the press
I Agree
Cancel

Press Releases

Jan 13, 2021

Johnson & Johnson COVID-19 Vaccine Candidate Interim Phase 1/2a Data Published in New England Journal of Medicine

Dec 28, 2020

Janssen Submits European Marketing Authorisation Application for Amivantamab for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Dec 21, 2020

Janssen Announces European Commission Authorisation of the First Complete Long-Acting Injectable HIV Treatment in Europe

Dec 18, 2020

Johnson & Johnson Announces Agreement in Principle with Gavi to Supply Janssen’s COVID-19 Vaccine Candidate to Lower-Income Countries in 2021

Dec 18, 2020

Johnson & Johnson Announces Its First Phase 3 COVID-19 Vaccine Trial ENSEMBLE is Fully Enroled

Dec 06, 2020

New Data Demonstrate Long-Term Benefit of IMBRUVICA® (ibrutinib) as First-Line Treatment for High-Risk Chronic Lymphocytic Leukaemia

View more Press Releases

Media Backgrounders

Neuroscience Backgrounder

Schizophrenia Backgrounder

Waldenström’s Macroglobulinemia (WM)

Stelara MOA infographic

The Role Of The Immune System In Crohn’s Disease

About Crohn’s Disease Backgrounder

VIEW MORE MEDIA BACKGROUNDERS

VIRTUAL ONCOLOGY PRESSROOM

Quick Links

 

Tweets

 

  • It's just over one week until the World Conference on Lung Cancer 🎉 The abstracts are now live and we're looking… https://t.co/xJ97bSccyj

    13 hours 9 min ago

Follow us on Twitter
SUBSCRIBE TO OUR YOUTUBE CHANNEL